[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:myelodysplastic-syndrome:hla-a-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Myelodysplastic Syndrome","HLA-A Gene",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05473910","A Phase 1\u002F3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)",[12],"Phase 1","RECRUITING","2026-08-26T02:16:50.548894Z","2026-07-19T19:36:05.117931Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05877599","A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation",[12],"2026-08-26T02:15:10.362237Z","2026-07-19T19:36:05.120541Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06315309","Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant",[26],"Phase 2","2026-08-26T02:16:48.735701Z","2026-05-05T02:43:29.662218Z"]